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ABSTRACT The structural proteins of the retroviral cap-
sid are translated as a polyprotein (the Gag precursor) that is
cleaved by a virally encoded protease. Processing of the human
immunodeficiency virus type 1 Gag precursor Pr55 was ana-
lyzed through a combination of pulse-chase labeling, cell
fractionation, and immunoprecipitation. We observed a mem-
brane-associated processing pathway for the Gag precursor
that gives rise to virions. In addition, we found that a significant
amount of processing occurs in the cytoplasm of infected cells
resulting in the intracellular accumulation of appropriately
processed viral proteins. This observation suggests the viral
protease is active in the cytoplasmic compartment of the cell.
Processing of the Gag protein was blocked in both compart-
ments by the addition of a viral protease inhibitor. A compar-
ison of the amount of cytoplasmic processing seen in lytically
infected cells with that seen in chronically infected cells showed
that cytoplasmic processing was associated with the lytic in-
fection. These observations raise the possibility that activation
of the human immunodeficiency virus type 1 protease in the
cytoplasm of lyticaly infected cells might result in the cleavage
of cellular proteins and thus contribute to cytotoxicity.
The last steps of replication of a virus include assembly of
new virions and release ofparticles from the infected cell. For
most retroviruses, these two processes are inextricably
linked; virion assembly occurs at the inner cell membrane as
the virus buds out of the infected cell (1-3). Virion particles
are formed from precursor proteins that are proteolytically
cleaved during the assembly process. However, the relation-
ship between virion assembly, protein processing, and virion
release is poorly understood.
The virion structural proteins of the human immunodefi-
ciency virus type 1 (HIV-1) are translated as a polyprotein,
the product of the gag gene, which is processed by a virally
encoded protease (4-7). The processing of the Gag precursor
protein Pr55 gives rise to the structural proteins of the viral
capsid: the matrix protein p17 (MA), the capsid protein p24
(CA), and the nucleocapsid protein p7 (NC) (Fig. 1). For most
retroviruses, the viral Gag precursor protein is synthesized in
the cytoplasm and directed to the cell membrane by myris-
toylation of the precursor (3, 8-12). With murine leukemia
virus, proteolytic processing of the Gag precursor requires
association of the precursor with the membrane and virion
assembly, such that mutations that block either of these
events also block cleavage ofthe Gag precursor (3, 9, 10, 13).
A Gag/Pol fusion protein is expressed at a level =5% that
of the Gag protein. In this precursor, protein sequences
encoded downstream of the gag gene in the pol gene are
linked to the Gag protein during translation (14). The pol gene
encodes viral enzymes used in replication, including, in the









FIG. 1. Gag precursor of HIV-1 and cleavage products. MA,
matrix protein; CA, capsid protein; NC, nucleocapsid protein.
Vertical lines indicate processing sites (4). The incompletely pro-
cessed proteins p25 and p15 are indicated.
the Gag and Gag/Pol precursors (7, 15, 16). Structural studies
of the protease reveal that it is an aspartic proteinase con-
sisting of two identical subunits that must dimerize to form
the active site (17-20). Dimerization of the protease subunits
to make an active protease, and thus initiate processing, must
occur between two Gag/Pol precursor molecules, an event
that by its concentration dependence would be favored
during virion assembly.
We have examined human cells infected with HIV-1 in an
effort to define the relationship between protein processing
and virion assembly. We identified two compartments in the
infected cell in which processing of viral capsid proteins
occurs: membrane-associated processing resulting in virion
formation and cytoplasmic processing leading to the accu-
mulation of soluble processed viral proteins in the cell
cytoplasm. The detection of processing in the cytoplasm of
infected cells suggests that activation of the viral protease
occurs in an inappropriate cellular compartment and this may
contribute to cell killing by this virus. Portions of this work
have been presented elsewhere.§
MATERIALS AND METHODS
Cells and Virus. CEM cells, a human T-cell lymphoma cell
line (a gift of M. Cloyd, University of Texas, Galveston),
were maintained in RPMI 1640 medium containing 10%o
(vol/vol) fetal calf serum. Four independent HIV-1 isolates
(205, 214, SKi, and G, a gift of M. Cloyd and R. Buckheit)
were used in these experiments (21). All experiments were
done with HIV-1G unless otherwise indicated. To infect cells,
virus was added to 2 x 106 CEM cells in a total volume of400
ILI in the well ofa 48-well plate for 2 hr, at which time the cells
were transferred to a T25 flask and fresh medium was added
to a total volume of 3 ml. The cells were pelleted and
suspended in fresh medium daily. The cultures were moni-
tored daily for cytopathicity and cell killing. Experiments
with acutely infected cells were performed at the point of
Abbreviations: HIV-1, human immunodeficiency virus type 1; MA,
matrix protein; CA, capsid protein; NC, nucleocapsid protein.
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maximal (i.e., 50%) cell killing. Chronic lines were estab-
lished by maintaining the acutely infected cells until the cells
surviving the acute infection grew out. Experiments with the
chronically infected cells were performed at about 14 days
after the initial infection when the viability of these cultures
was between 85% and 90%.
Analysis of Viral Proteins: Fractionation and Immunopre-
cipitation. Infected cells were pulse-labeled with either 150
gCi of [35S]methionine per ml (1000 Ci/mmol; 1 Ci = 37 GBq;
New England Nuclear) or 500 gCi of [3H]leucine per ml (50
mCi/mmol; New England Nuclear) for 20 min. The cells were
washed with cold phosphate-buffered saline (PBS) at the end
of the labeling period and then suspended in complete me-
dium, which includes 0.1 mM methionine and 0.4 mM
leucine. Aliquots containing 2 x 106 cells were removed at the
end of the pulse period and at various intervals during the
chase period. The cells were pelleted from the aliquot and the
remaining medium was frozen and designated supernatant
virus. All cell fractionation manipulations were performed at
40C following published procedures (9). The cells were
washed in PBS and suspended in swelling buffer (10 mM
KCl/20 mM Tris HCI, pH 7.8/1 mM EDTA/0.1% 2-mercap-
toethanol/1% Trasylol). After 20 min at 40C, the cells were
lysed using a tight-fitting "B" glass Dounce homogenizer.
Nuclei were pelleted by centrifugation at 1000 x g for 5 min.
The supernatant from this spin was centrifuged at 100,000 x
g for 30 min to pellet the membranes. The resulting super-
natant (S100 supernatant) was frozen and the pellet (S100
pellet) was suspended in a RIPA buffer (0.15 M NaCl/20mM
Tris HCl, pH 7.4/2 mM EDTA/1% Triton X-100/1% sodium
deoxycholate). The fractionation was validated using unin-
fected CEM cells and subjecting each of the fractions to
SDS/polyacrylamide gel electrophoresis and Western anal-
ysis using a monoclonal antibody to CD4. All of the stainable
protein appeared in the membrane fraction (data not shown).
Infected cells were also labeled with 500 ,uCi of [3H]myristic
acid per ml (50 mCi/ml; New England Nuclear) for 12 hr.
These cells were then fractionated as described above.
To isolate labeled viral proteins, the samples were incu-
bated for 1 hr at 4°C with serum from a HIV-1 seropositive
person. The immune complexes were collected by binding to
protein A-Sepharose (Pharmacia) followed by centrifugation.
The complexes were washed three times in RIPA buffer,
suspended in a SDS loading buffer, and boiled for 2-3 min.
The samples were then loaded on a SDS/12% polyacrylamide
gel (22). After electrophoresis the gel was dried under vac-
uum and then exposed to x-ray film. Gels containing proteins
labeled with 3H were treated with EN3HANCE according to
the instructions of the manufacturer (New England Nuclear).
In some cases, radioactivity in the dried gel was quantitated
using a radioanalytical analyzing system (AMBIS Systems,
San Diego).
Inhibition of the Viral Protease. Infected cells were main-
tained in the presence of one of two inhibitors of the viral
protease (kindly provided by Thomas Meek and Geoffrey
Dryer, SmithKline Beecham). The cells were grown for 1 hr
in methionine-deficient medium that contained one of the
inhibitors at a concentration of 20 uM. Labeling was then
carried out for 6 hr with 150 uCi/ml in the presence of the
inhibitor. Aliquots containing 2 x 106 cells were removed and
the cells were fractionated into cytoplasmic, membrane, and
supernatant components as described above.
RESULTS
Pulse-Chase Labeling and Cell Fractionation of Acutely
Infected Cells Reveal Processing in Two Cellular Compart-
ments. In an effort to define the temporal order of events in
HIV-1 virion formation we examined the intracellular site of
viral protein processing. Viral proteins were analyzed by
combining pulse-chase analysis with subcellular fraction-
ation at the peak of cell killing, which occurred -5 days after
infection. Cellular and viral proteins were pulse-labeled with
[35S]methionine for 20 min followed by a chase period in the
presence of unlabeled methionine. At various times during
the chase, cells were removed and fractionated into cell
supernatant (containing released virus particles), a nuclear
fraction, a cytoplasmic fraction, and a membrane fraction.
Viral proteins in each fraction were isolated by immunopre-
cipitation using human serum obtained from a HIV-1 serop-
ositive person. The proteins were then analyzed by SDS/
polyacrylamide gel electrophoresis followed by autoradiog-
raphy. The results are shown in Fig. 2. In the cytoplasmic and
membrane fractions the Gag precursor Pr55 was present at
the end of the pulse-labeling period. At 30 min into the chase
period the membrane fraction had small and equivalent
amounts of two proteolytically processed forms of CA, p25
and p24, which differ by a short C-terminal extension in the
longer protein (23, 24). The mature p24 species predominated
by 60 min in the membrane fraction and was the only species
apparent at 3 hr. This relationship between p25 and p24 was
also seen in extracellular virus. At 15 min equivalent amounts
of p25 and p24 were present in virus. During the rest of the
chase period p24 predominated. The similarity in these two
patterns is consistent with the interpretation that proteolytic
processing involved in virion formation occurs either at the
membrane during virion formation or rapidly after virus
budding.
Surprisingly, the processing of viral proteins was not
restricted to the membrane fraction. A portion of the Pr55
Gag precursor present in the cytoplasm at the end of the
chase period persisted with some of it being replaced by the
p25 and p24 forms of CA (Fig. 2). The p25 intermediate
appeared initially, and by 60 min there were equivalent
amounts of the two forms ofCA (p25 and p24). This situation
persisted through 3 hr and even to 14 hr (not shown). Other
processing intermediates are seen below Pr55 at the end of





FIG. 2. Pulse-chase analysis of viral proteins from different
fractions of infected cells. CEM cells were infected with stock virus
(HIV-1G) and the labeling was performed at the peak of cell killing
(5 days after infection). Lanes 1-5, cytoplasmic fraction (S100
supernatant); lanes 6-10, membrane fraction (S100 pellet); and lanes
11-15, extracellular fraction (supernatant virus). Samples were taken
at the end ofthe chase period (lanes 1, 6, and 11), after 15 minofchase
(lanes 2, 7, and 12), after 30 min of chase (lanes 3, 8, and 13), after
1 hr of chase (lanes 4, 9, and 14), and after 3 hr of chase (lanes 5, 10,
and 15). Each sample was immunoprecipitated and analyzed by
polyacrylamide gel electrophoresis. The positions of p55 Gag and the
two forms of CA p25 and p24 are indicated on the left.
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the pulse (Fig. 2), and steady-state levels of the p4l inter-
mediate (MA/CA) are seen in the cytoplasm using Western
analysis (data not shown) (25). Processing in the cytoplasmic
fraction was similar to processing that occurs in the mem-
brane fraction but was clearly distinct: the two forms of CA
remained in equivalent amounts in the cytoplasmic fraction,
whereas the p24 form predominated in the membrane fraction
and in virions. Similar results were obtained with three
additional independent HIV-1 isolates, although the persis-
tence of p25 in the cytoplasmic fraction was not seen with all
isolates or resolved in all experiments (data not shown).
The fact that the processed products found in the cyto-
plasm resembled the products found in the membrane and in
supernatant virus fractions suggested the viral protease was
responsible for all of the observed processing. To provide a
test of this hypothesis we analyzed the extent of processing
in each compartment in the presence of a viral protease
inhibitor. Pulse-chase labeling experiments were carried out
in the presence of two synthetic analogues of one of the
protease cleavage sites (26). We found that processing was
inhibited in the membrane and cytoplasmic fractions in the
presence of both viral protease inhibitors (data not shown).
These results support the conclusion that the processed
proteins that appear in these two compartments are proc-
essed by the viral protease and not by a cellular protease.
MA Accumulates to a Lesser Extent than CA in the Cyto-
plasm ofAcutely Infected Cells. The Gag precursor is normally
directed to the membrane through the addition of an N-ter-
minal myristic acid moiety (11, 12). To determine what role
myristoylation might play in the accumulation ofcytoplasmic
protein, we labeled cells for 12 hr with [3H]myristic acid and
looked for the distribution of labeled viral proteins in the
different fractions. Labeled Pr55 Gag and p17 MA were
present in the membrane fraction and labeled p17 accumu-
lated in the virus fraction, but no labeled viral proteins were
detected in the cytoplasmic fraction (data not shown). La-
beling of Gag in the cytoplasmic fraction was not expected
since Gag turned over during this long labeling period, but the
absence of labeled p17 suggested that either the proteins that
persisted in the cytoplasm were not myristoylated or that the
p17 MA product was reduced in this fraction. To determine
which of these possibilities was correct, we examined p17 in
each fraction. First, we pulse labeled cells with [3H]leucine
and followed the fate of p24 CA and p17 MA in the different
fractions during the chase period (Fig. 3). The p24 CA
product accumulated in the cytoplasmic and virus fractions
with time. In the membrane fraction CA first increased and
then decreased as it was chased into virions. The p17 MA
product behaved similarly in the membrane and virion frac-
29-
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FIG. 3. Pulse-chase analysis ofp17 MA. Cells were pulse labeled
for 20 min with [3H]leucine (lanes 1, 4, and 7) and then chased for
either 1 hr (lanes 2, 5, and 8) or 3 hr (lanes 3, 6, and 9). For each time
point, the cells were fractionated into a cytoplasmic fraction (lanes
1-3), a membrane fraction (lanes 4-6), and a supernatant virus
fraction (lanes 7-9). Each fraction was immunoprecipitated and
analyzed by polyacrylamide gel electrophoresis. Molecular mass
markers (in kDa) are shown on the left. The positions of p24 CA and
p17 MA are shown on the right. Lane C is an immunoprecipitate of
a lysate of labeled uninfected cells.
tions, but this protein was significantly underrepresented in
the cytoplasmic fraction. This analysis was complicated by
what appears to be a general underrepresentation of p17 in
each fraction (p17 and p24 have a similar number of leucines
that can be labeled and are made in equimolar amounts). This
difference may be due to differing affinities by the antibodies
in the immunoprecipitating serum. However, the specific
underrepresentation of p17 in the cytoplasmic fraction was
confirmed by analysis of steady-state levels of protein. Using
Western analysis to measure the steady-state level ofprotein,
we estimate that only 25% of the expected MA is present in
the cytoplasm based on the amount of CA in this fraction
(data not shown). We do not know ifthe unaccounted for p17
MA is myristoylated and directed to the membrane fraction
or turned over and lost in the cytoplasmic fraction. The
remaining portion ofGag encodes p7 NC, which first appears
as an intermediate with the C-terminal p6 protein as a 15-kDa
protein, p15 (ref. 27; Fig. 1). Western analysis of each
fraction using a monoclonal antibody to p6 (27) revealed that
although the mature product, p6, was present in the mem-
brane and the virus fractions only the p15 precursor was seen
in the cytoplasm (data not shown).
Cytoplasmic Processing Does Not Occur in Chronically
Infected Cells. The occurrence of accurate cytoplasmic proc-
essing of the viral precursor proteins suggested that the viral
protease was active in this fraction of the cell. An inappro-
priately active protease in the cytoplasm of the cell is a
potential source of toxicity. One test of this possibility is to
examine the extent of cytoplasmic processing in cells chron-
ically infected with HIV-1. Infection of CEM cells with
HIV-1 in vitro results in extensive cell death followed, at
about 14 days, by the appearance of cells that are chronically
infected. These survivor cells produce viral proteins but are
not killed. To evaluate further the role of processing in this
noncytopathic infected state, chronic lines were established
from eight independent infections ofCEM cells with the same
virus isolate. The cells were labeled with [35S]methionine for
20 min and the labeled proteins were chased with complete
medium for 1 and 3 hr. The cells were fractionated and viral
proteins were isolated by immunoprecipitation and analyzed
by polyacrylamide gel electrophoresis. Processing in all eight
lines occurred primarily at the membrane, with only a small
amount of p25/24 accumulating in the cytoplasm after a 3-hr
chase (data not shown). The extent of processing was quan-
titated for three of the cell lines; a graphic comparison of the
loss of Pr55 and the accumulation of cytoplasmic p25/24 in
the cytoplasmic fraction of cells from two acute and three
chronic infections is shown in Fig. 4. These results indicate
virtually no cytoplasmic processing in the chronically in-
fected cells while the Gag precursor is chased from this
compartment. Thus, increased cell viability is correlated with
a reduced amount of cytoplasmic processing of the viral Gag
protein.
DISCUSSION
HIV encodes the Gag and Gag/Pol precursor proteins, Pr55
and Pr160, respectively, which, when processed into the
mature proteins, subserve the structural and enzymatic re-
quirements of the virus. Accurate processing of these pre-
cursors is an obligatory step in the formation of an infectious
virion and is accompanied by a readily observable structural
rearrangement in which the immature particles attain the
more condensed core characteristic of an infectious particle
(5, 7). The viral Gag precursor is directed to the cell mem-
brane by myristoylation of the precursor. Although process-
ing of the Gag precursor is thought to be a late event in the
maturation of the murine and avian oncoviruses (3, 4), the
location of processing has not been determined for HIV or the
other lentiviruses. We have identified two compartments in
Proc. Natl. Acad Sci. USA 88 (1991)
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FIG. 4. Comparison of cytoplasmic processing in chronically and
acutely infected cells. Acutely and chronically infected cells were
pulse-labeled with [355]methionine and then chased with complete
medium. Aliquots of cells were removed at intervals during the chase
period, the cells were fractionated, and the viral proteins were
immunoprecipitated. Radioactivity in the dried gels was quantitated
by a radioanalytical analyzing system (AMBIS Systems). The total
radioactivity present in the cytoplasm as p55 and as p24/p25 is
plotted versus time of chase. (A) Acute infection for two different
experiments. The lines with open squares represent data from Fig. 2.
The other experiment was similar to that shown in Fig. 2 in that at
the long chase times there were equal amounts of p25 and p24. (B)
Chronic infection from three experiments. Closed symbols gild solid
lines represent p55; open symbols and dashed lines represern p24/25,
respectively, for the individual experiments.
cells acutely infected with HIV-1 where processed viral
proteins are found: in the membrane, where processing gives
rise to virions, and in the cytoplasm, where processing results
in the accumulation of processed viral capsid protein.
Processing of viral Gag and Gag/Pol proteins could be
occurring either at the membrane or at both the membrane
and in the cytoplasm. In the former case, the appearance of
processed viral proteins in the cytoplasm could be the result
of a breakdown of virion assembly at the membrane with
release of viral proteins into the cytoplasm. Alternatively,
viral proteins may accumulate in the cytoplasm at high
enough levels to permit activation of the viral protease. A
high level of viral protein is one of the features of acute HIV-1
infection (28), and the potential for cytoplasmic processing
has been demonstrated using a mutant viral genome that
encodes a Gag protein that cannot be myristoylated (11). In
this case, high level expression was obtained after transfec-
tion and amplification of viral DNA in COS cells, and
cell-associated processing ofGag proteins was observed. We
have observed in the cytoplasm of acutely infected cells (i)
the presence of mature products of processed Gag protein
(p17 MA and p24 CA), (ii) processing intermediates (p41,
p25, and p15), and (iii) a dynamic change in the ratio of the
p25 intermediate and the p24 product over time that was
slower than the processing associated with virion formation.
These features of viral protein processing were not seen in the
cytoplasm of chronically infected cells. Taken together, the
evidence suggests that the viral protease is active in the
cytoplasmic fraction of acutely infected cells and capable of
processing viral Gag protein that persists in the cytoplasm.
The mechanisms by which viruses kill cells during lytic
infection are poorly understood. One mechanism for HIV-
1-induced cell killing is through cell fusion, or syncytium
formation, mediated by the viral env gene product (29).
However, in many circumstances cell killing by HIV-1 occurs
in the absence of significant syncytium formation and there-
fore alternative mechanisms of cell killing must be considered
(30). Lytic infections by retroviruses have been correlated
with the appearance of large amounts of unintegrated viral
DNA (31), utilization of a specific cellular receptor (32), and
the production of large amounts of viral protein (28). These
observations suggest that one feature of cell killing is the
ability to carry out efficient initial infection, perhaps aug-
mented by a period of efficient reinfection. Perturbations in
phospholipid synthesis (33) and calcium metabolism (34)
have also been identified in infected cells and may play a role
in viral pathogenesis.
In several picornavirus systems, where processing of viral
precursor proteins and virion assembly occur in the cyto-
plasm, a viral protease has been implicated in cell killing.
These proteases may inhibit the function of several cellular
proteins, including histone 3 (35) and a subunit of the cap-
binding protein complex (36). Thus, the action of a viral
protease on cellular proteins can contribute to the cell
toxicity associated with virus replication.
Dimerization is required to form the active site of the
HIV-1 protease and thus presumably required for activity.
Therefore, proteolytic cleavage (of either viral or possibly
cellular proteins) can occur only in those situations in which
the concentration of the protease is sufficiently high to permit
dimerization. The high intracellular viral protein concentra-
tion noted for certain HIV-1-infected cells (28) may provide
the opportunity for premature dimerization and activation of
the viral protease. Although specific cellular targets of the
HIV-1 protease have not been identified, it is clear that the
viral protease is toxic when expressed at high levels in
bacteria (16, 37, 38), and it is able to cleave heterologous
proteins (39, 40). Furthermore, injection of purified protease
directly into mammalian cells resulted in altered cell mor-
phology (40). Our observation of processing of viral proteins
in the cytoplasm of infected cells indicates that the HIV-1
protease is active in an inappropriate cellular compartment
during lytic infection, which suggests another mechanism for
HIV-1-induced cell toxicity.
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